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S U M M A R Y
Objectives: In this open-label, non-randomized phase II study, the safety and immunogenicity of a fully
liquid diphtheria–tetanus–whole cell pertussis–hepatitis B–Haemophilus inﬂuenzae type b (DTPw–
HepB–Hib) combination vaccine (Quinvaxem1) were assessed in infants who had or had not received a
birth dose of hepatitis B (HepB) vaccine.
Study design: Two groups of infants, ‘HepB at birth’ (n = 110) and ‘no HepB at birth’ (n = 108), were
enrolled and received a primary vaccination course using a 2–4–6 months schedule.
Results: Seroprotection/seroconversion rates of>95% were achieved against all antigens included in the
combination vaccine for both study groups. Although signiﬁcantly higher anti-hepatitis B virus
(p < 0.001) and anti-tetanus (p = 0.031) antibody titers were achieved in group ‘HepB at birth’ when
compared with group ‘no HepB at birth’, the proportion of ‘no HepB at birth’ subjects achieving
protective titers was non-inferior to the proportion of subjects in group ‘HepB at birth’. The birth dose of
HepB vaccine did not seem to inﬂuence the safety pattern of the DTPw–HepB–Hib combination vaccine.
Conclusions: The present study demonstrated that the fully liquid DTPw–HepB–Hib vaccinewas safe and
immunogenic when administered using a 2–4–6 months immunization schedule, regardless of whether
or not infants had received a dose of HepB vaccine at birth.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The combined vaccine against diphtheria, tetanus and pertussis
(DTP) is the core vaccine in childhood immunization programs and
is included in the Expanded Programme on Immunization (EPI).1–3
In addition, the World Health Organization (WHO) has recom-
mended the inclusion of vaccination against hepatitis B virus (HBV)
since 1992 and Haemophilus inﬂuenzae type b (Hib) since 1997 in
the EPI.4–6 In regions where HBV infection is endemic, hepatitis B
vaccination (HepB vaccination) in infancy has been shown to be
highly effective in preventing HBV infection, chronic carriage, and
primary liver cancer.7,8
Four licensed pentavalent diphtheria–tetanus–whole cell
pertussis–hepatitis B–H. inﬂuenzae type b (DTPw–HepB–Hib)
combination vaccines are currently prequaliﬁed by the WHO.9–* Corresponding author. Tel.: +41 31 980 6251; fax: +41 31 980 6772.
E-mail address: christian.herzog@crucell.ch (C. Herzog).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.09.00415 The earlier generations of these vaccines consist of a DTPw–
HepB component and a separate lyophilized Hib component that
has to be reconstituted before use, while newer ones are available
as fully liquid suspensions. Quinvaxem1 is a fully liquid DTPw–
HepB–Hib combination vaccine; it is ready to use and therefore
eliminates additional on-site handling procedures. Quinvaxem has
been shown to be safe and immunogenic when administered in a
2–3–4 months primary vaccination schedule,16 and was licensed
and prequaliﬁed by the WHO in 2006.
Since the highest risk of HBV transmission is from a hepatitis B
surface (HBs) and/or hepatitis B envelope (HBe) antigen-positive
mother to her newborn child, it is recommended that infants in
highly endemic areas receive a HepB vaccine dose within 12 h of
birth, followed by two additional doses.17 Inclusion of HepB
vaccine in combination childhood vaccines will help to increase
the coverage of HepB immunization and minimize the number of
doctor visits and injections received by the infant. However, the
use of HepB-containing combination vaccines results in infants
receiving an additional, fourth dose of HepB vaccine. The safety andses. Published by Elsevier Ltd. All rights reserved.
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previously been demonstrated.18–21 It has also been shown that a
single dose of HepB vaccine at birth has no adverse impact on
immunogenicity and safety of DTP–HepB-containing vaccines
administered according to a variety of schedules.22–25
The objective of the current study was to assess the
immunogenicity, tolerability, and safety of a primary vaccination
course with the DTPw–HepB–Hib vaccine, when administered in a
2–4–6 months schedule to infants who had, or had not, received a
birth dose of amonovalent HepB vaccine. According to the national
EPI schedule in Argentina, the primary immunization course, as
applied in this study, was to be followed by a DTPw–Hib
vaccination at 18 months of age. Although it was not part of the
study procedure, all children were followed-up to ensure they
received this fourth dose.
2. Methods
2.1. Study design
The current study was a non-randomized, open-label, single-
centre study conducted between April 2005 and May 2006 at the
Hospital de Nin˜os Ricardo Gutierrez in Buenos Aires, Argentina.
Infants between 6 and 12 weeks of age, and free of obvious health
problems as assessed by the investigator, participated in the study.
Infants who were born before 37 weeks of gestation, with a birth
weight below 2500 g, or who had previously received any dose of
Hib and/or DTP vaccines were excluded from the study.
A single dose of HepB vaccine given as soon as possible after
birth, regardless of the infection status of the mother, is part of the
national EPI in Argentina. Because the assignment to treatment
groups was dependent on the HepB vaccination status of subjects
before study enrolment, the allocation was not randomized. In
order to ensure that enough infants were eligible for the group ‘no
HepB at birth’, the following procedurewas used: pregnantwomen
were screened for HBV infection, and those testing negative were
invited to have their child participate in group ‘no HepB at birth’ of
the study. In order for infants to be included in this group, the
mothers had to agree not to have their child vaccinated with HepB
vaccine at birth. Children brought to the study centre for the usual
EPI vaccinationwho had received one dose of HepB vaccine at birth
were eligible for enrolment into group ‘HepB at birth’ of the study.
It was planned to have 220 subjects enrolled into the study, in a 1:1
ratio in the two groups according to their HepB vaccination status.
Three doses of the DTPw–HepB–Hib vaccine were administered
at 2, 4, and 6 months of age according to the schedule adopted by
Argentina. The vaccine was administered intramuscularly into the
right thigh. Blood samples for evaluation of the primary objective
of this study were obtained prior to the ﬁrst vaccination (baseline),
and 1 month after the third vaccination. An additional sample was
taken just prior to the third vaccination (data not shown). Oral
polio vaccine was concomitantly administered to all infants.
The study protocol with all amendments and informed consent
forms were approved by the appropriate independent ethics
committee, and the study was performed in compliance with the
Declaration of Helsinki, Good Clinical Practice guidelines (GCP) and
local laws. Written informed consent to participate in the study
was obtained from the parent(s)/legal guardian(s) of all subjects
before enrolment into the study.
2.2. Vaccines
Each DTPw–HepB–Hib fully liquid vaccine dose contained 0.5
ml: 30 IU diphtheria toxoid (D), 60 IU tetanus toxoid (T), 4 IU
inactivated whole cell Bordetella pertussis (Pw), 10mg H. inﬂuenzae
type B (Hib) polyribosyl ribitol phosphate (PRP) oligosaccharideconjugated to approximately 25 mg of CRM197 protein, and 10 mg
puriﬁed HBV surface antigen (HBsAg). The D, T, Pw, and Hib
antigens were identical to the antigens used in QuattvaxemTM
(Novartis Vaccines and Diagnostics, formerly Chiron Vaccines,
Siena, Italy) and the HBsAg was identical to the antigen used in
Hepavax-Gene1 (Crucell Berna Biotech Korea Corp., formerly
Green Cross Vaccine Corporation). The DTPw–HepB–Hib vaccine
was developed and manufactured by Crucell Berna Biotech Korea
Corp. Production was performed according to GoodManufacturing
Practice (GMP) guidelines.
2.3. Immunogenicity assessment
Blood sampleswereanalyzedbyenzyme-linked immunosorbent
assays (ELISAs) for the presence of antibodies. HBV seroprotection
was deﬁned as an anti-HBs antibody level of 10 IU/l.26 Anti-
diphtheria andanti-tetanusantibodies at a concentrationof0.1 IU/
ml were considered protective.27,28 Antibodies against B. pertussis
were determined using a whole-cell ELISA.29 Since a correlate for
seroprotection against B. pertussis has not yet been established,
seroconversion was deﬁned as either titer levels20 ELISA IU (EIU)
or a 4-fold increase over baseline titers. Antibodies against Hib PRP
were measured by ELISA,30 and seroprotection rates were assessed
according to the two commonly used cut-off levels: anti-PRP 0.15
mg/ml and 1.0 mg/ml.
Anti-diphtheria toxoid, anti-tetanus toxoid, anti-PRP and anti-
HBs assays were performed at Novartis Vaccines and Diagnostics
(formerly Chiron Vaccines), Clinical Serology, Marburg, Germany.
The anti-B. pertussis antibody ELISA was performed at the
University of Turku, Department of Medical Microbiology, Turku,
Finland.
2.4. Safety and reactogenicity assessment
Solicited local adverse events (AEs; tenderness, erythema and
induration) and systemic AEs (fever, rash, change in eating habits,
sleepiness, unusual crying, persistent crying, irritability, vomiting
and diarrhea) were recorded by the subject’s parent(s) or legal
guardian(s) on a diary card for a 7-day period after each vaccination.
Fever was deﬁned as an axillary temperature 38.0 8C31 and
persistent crying as unaltered crying >3 h.32 Subjects were
monitored by study personnel for 1 h after each vaccination, and
the parent(s) or legal guardian(s) were further contacted by
telephone at 2–3 days and again at 7–8 days after each vaccination
to assess the daily axillary temperature, the occurrence of AEs, and
the use of concomitant medication. Unsolicited AEs and serious
adverse events (SAEs) were recorded throughout the study period.
2.5. Statistical analysis
The primary objective of this studywas to assess non-inferiority
of the anti-HBs seroprotection rate induced by the HBV component
of DTPw–HepB–Hib in subjects who had received a HepB
vaccination at birth (‘HepB at birth’) compared to subjects who
had not received a HepB vaccination at birth (‘no HepB at birth’). In
addition, seroprotection rates for the other antigens included in the
combination vaccine (seroconversion rates for B. pertussis) were
also assessed in both study groups. Comparison between the two
study groups was based on a non-inferiority limit of 10% (lower
limit of the two-sided 90% conﬁdence interval (CI) >10%).
Calculations of geometric mean titers (GMTs) were performed
by taking the anti-log10 of the mean of the log10 titer transforma-
tions. The GMTs were calculated together with the corresponding
95% CIs (normal approximation).
The sample size was calculated based on the primary objective
assuming a reference seroprotection to HBs of 95% and a non-
Table 1
Study population and demographic characteristics
HepB at birth No HepB at birth
n % n %
Number of subjects enrolled/vaccinated 110 100 108 100
Evaluateda
Safety 107 97.3 103 95.4
ATP 103 93.6 100 92.6
Demographic characteristics (safety population)
Male/female 61/46 57.0/43.0 53/50 51.5/48.5
Mean age, months (range) 2.1 (1.4–2.7) 2.0 (1.5–2.8)
Mean weight, kg (range) 5.4 (3.7–7.6) 5.3 (3.9–6.9)
HepB, hepatitis B vaccine; ATP, according-to-protocol.
a Percentages based on all vaccinated subjects.
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per group was required to demonstrate, with a power of 90% and a
one-sided signiﬁcance level of 5%, the non-inferiority between
subjects having received HepB vaccine at birth and subjects not
having received HepB vaccine at birth. Considering possible
dropouts, the sample size was increased by a suitable amount of
15% for a total of 220 eligible subjects to be allocated to the study
groups according to HepB vaccination status. Sample size
estimation was performed using the Anderson–Hauck correction
for proportions. SAS 8.1 software (SAS Institute, Cary, NC, USA) was
used for the statistical analysis.
3. Results
3.1. Subjects and demographics
Of 260 infants screened, 218 infants were enrolled in the study
and received at least the ﬁrst DTPw–HepB–Hib vaccination (Table
1). Parents declined participation for general reasons, because of
blood extraction, travel or not having access to a phone. For eight
of the infants enrolled, no follow-up safety data were provided.
Thus, the safety population included 210 subjects. Fourteen
vaccinated infants did not complete the study period. Among
these, two subjects discontinued due to AEs (one subjectTable 2
Seroprotection and seroconversion rates at baseline (prior to the ﬁrst vaccination) and 1m
a single dose hepatitis B vaccine at birth (HepB at birth) or not (no HepB at birth); AT
Baseline
HepB at birth, n=103 No HepB at
Hepatitis B
% SP 20.8 5.0
Absolute difference (90% CI)
Hib (anti-PRP 0.15 mg/ml)
% SP 51.5 43.4
Absolute difference (90% CI)
Hib (anti-PRP 1.0 mg/ml)
% SP 12.6 14.1
Absolute difference (90% CI)
Diphtheria
% SP 75.7 78.6
Absolute difference (90% CI)
Tetanus
% SP 99.0 100
Absolute difference (90% CI)
Pertussis
% SC 2.0 0.0
Absolute difference (90% CI)
ATP, according-to-protocol; CI, conﬁdence interval; % SC, seroconversion rate (pertussi
a Non-inferiority concluded if the lower limit of the two-sided 90% CI is >10% forexperienced hypertonia and metabolic acidosis and the other
subject died of sudden infant death syndrome), consent was
withdrawn for three subjects, six subjects moved from the study
area, and threewere lost to follow-up. In addition, one subjectwas
excluded from the immunogenicity analysis because the fourth
study visit was outside the speciﬁed time window. Consequently,
data from 203 infants (HepB at birth, n = 103; no HepB at birth,
n = 100) included in the according-to-protocol (ATP) population
were used for the primary immunogenicity analysis. The
demographic characteristics of the two study groups (safety
population) were similar (Table 1).
3.2. Immunogenicity
All but one subject (99.0%, 90% CI 94.7–100%) in the ‘HepB at
birth’ group and 97.0% (90% CI 91.5–99.4%) in the ‘no HepB at birth’
group had seroprotective anti-HBs antibody levels (10 IU/l) 1
month after the third dose. The difference in seroprotection rates
between the two groups was 2.0% (90% CI 1.2–5.3%). Since the
lower conﬁdence limit of the group difference is above 10.0%,
non-inferiority between the groups can be concluded and the
primary study objective was met (Table 2).
Similarly, there were no signiﬁcant differences between the
groups in the analyses of the other antigens. All subjects (100%) inonth after the third vaccination with DTPw–HepB–Hib in infants who had received
P population
Post-third vaccination
birth, n=100 HepB at birth, n=103 No HepB at birth, n=100
99.0 97.0
2.0 (1.2, 5.3)a
98.0 99.0
1.0 (3.8, 1.9)a
87.1 89.9
2.8 (10.2, 4.7)
96.1 100
3.8 (7.6, 0.0)a
100 100
0.0 (2.2, 2.3)a
95.1 98.0
2.9 (7.1, 1.4)a
s only); % SP, seroprotection rate.
the absolute difference between the groups.
Table 3
Geometric mean titers at baseline (prior to the ﬁrst vaccination) and 1 month after the third vaccination with DTPw–HepB–Hib in infants who had received a single dose
hepatitis B vaccine at birth (HepB at birth) or not (no HepB at birth); ATP population
Baseline Post-third vaccination
HepB at birth, n=103 No HepB at birth, n=100 HepB at birth, n=103 No HepB at birth, n=100
Hepatitis B
GMT (IU/l) 5.25 3.54 560.99 281.31
95% CI 4.28, 6.44 2.90, 4.32 439.96, 715.3 221.92, 356.58
p-Valuea 0.007 <0.001
Hib
GMT (mg/ml) 0.162 0.153 9.564 13.494
95% CI 0.123, 0.213 0.113, 0.208 6.665, 13.724 9.701, 18.769
p-Valuea 0.787 0.165
Diphtheria
GMT (IU/ml) 0.292 0.336 0.997 0.905
95% CI 0.209, 0.407 0.239, 0.471 0.812, 1.224 0.753, 1.088
p-Valuea 0.556 0.486
Tetanus
GMT (IU/ml) 1.980 2.335 5.353 3.832
95% CI 1.627, 2.408 1.937, 2.815 4.346, 6.594 3.063, 4.794
p-Valuea 0.228 0.031
Pertussis
GMT (EIU) 4.04 4.22 45.01 43.25
95% CI 3.50, 4.66 3.70, 4.82 40.79, 49.68 39.17, 47.76
p-Valuea 0.657 0.572
ATP, according-to-protocol; GMT, geometric mean titer; CI, conﬁdence interval; IU, international units; EIU, ELISA international units.
a Two-sided p-values are based on 90% CI calculated using normal approximation.
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96.1% where protected in the ‘HepB at birth’ group compared to
100% in the ‘no HepB at birth’ group. Seroconversion to B. pertussis
was achieved in 95.1% of the subjects in the ‘HepB at birth’ group
compared to 98.0% in the ‘no HepB at birth’ group. When the anti-
PRP0.15mg/ml cut-off level was applied, 98.0% of the subjects in
the ‘HepB at birth’ group were protected against Hib compared
with 99% in the ‘no HepB at birth’ group, demonstrating non-
inferiority after the third vaccination, as with tetanus and
diphtheria. However, non-inferiority could not be demonstrated
when the anti-PRP 1.0 mg/ml cut-off level was applied (87.1% of
the subjects in the ‘HepB at birth’ group were protected compared
with 89.9% in the ‘no HepB at birth’ group).
The ‘HepB at birth’ group had signiﬁcantly higher anti-HBs
GMTs at all time-points of the analysis. After completion of the
primary vaccination course, the GMT of the ‘HepB at birth’ group
(560.99 IU/l, 95% CI 439.96–715.3 IU/l) was approximately doubleTable 4
Rate of subjects with solicited local and systemic events reported from ﬁrst to third va
First vaccination Secon
HepB at birth
n=106 (100%)
No HepB at birth
n=102 (100%)
HepB
n=10
Local
Erythema 24 (22.6) 32 (31.4) 25 (2
Induration 47 (44.3) 48 (47.1) 40 (3
Tenderness 94 (88.7) 93 (91.2) 78 (7
Systemic
Change in eating habits 34 (32.1) 37 (36.3) 23 (2
Diarrhea 18 (17.0) 10 (9.8) 10 (9
Fevera 24 (22.6) 29 (28.4) 15 (1
Irritability 91 (85.8) 89 (87.3) 73 (7
Rash 2 (1.9) 2 (2.0) 1 (1.0
Sleepiness 49 (46.2) 49 (48.0) 30 (2
Unusual crying 1 (0.9) 0 (0) 0 (0)
Persistent cryingb 0 (0) 0 (0) 0 (0)
Vomiting 6 (5.7) 9 (8.8) 5 (4.9
Results are n (%). HepB, hepatitis B vaccine.
a Axillary temperature 38 8C.
b Unaltered crying lasting >3h.that of the ‘no HepB at birth’ group (281.31 IU/l, 95% CI 221.92–
356.58 IU/l). Although statistically signiﬁcant, the difference
between the groups is not considered clinically relevant, as titers
are well above the seroprotective level in both groups and also a
very large increase in GMT over the baseline (approximately 110-
fold in the ‘HepB at birth’ group and approximately 80-fold in the
‘no HepB at birth’ group) was shown. After the third vaccination,
the anti-tetanus GMTs were signiﬁcantly higher for the ‘HepB at
birth’ group than for the ‘no HepB at birth’ group (p = 0.03). All
other GMTs were similar between the two study groups (Table 3).
3.3. Safety and reactogenicity
There were no marked differences in the rates, severity, or
duration of solicited AEs after vaccination with DTPw–HepB–Hib
between the infants who had received a birth dose of HepB vaccine
and thosewho had not. The number of subjects reporting feverwasccination; safety population
d vaccination Third vaccination
at birth
3 (100%)
No HepB at birth
n=101 (100%)
HepB at birth
n=103 (100%)
No HepB at birth
n=101 (100%)
4.3) 27 (26.7) 37 (35.9) 25 (24.8)
8.8) 37 (36.6) 51 (49.5) 30 (29.7)
5.7) 79 (78.2) 69 (67.0) 63 (62.4)
2.3) 19 (18.8) 17 (16.5) 22 (21.8)
.7) 11 (10.9) 9 (8.7) 7 (6.9)
4.6) 19 (18.8) 24 (23.3) 29 (28.7)
0.9) 71 (70.3) 69 (67.0) 58 (57.4)
) 2 (2.0) 7 (6.8) 0 (0)
9.1) 30 (29.7) 20 (19.4) 28 (27.7)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
) 6 (5.9) 8 (7.8) 7 (6.9)
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comparedwith the ‘HepB at birth’ group (40.6%). During the course
of vaccination, the rates of most AEs tended to decrease. The
majority of AEs were reported within 1 day post-vaccination and
resolved within 2 to 4 days.
Tenderness was the most frequently reported local AE, but
decreased throughout the course of vaccination (Table 4). Most
events of erythema and induration were classiﬁed as clinically
insigniﬁcant, and only minor differences were observed for the
incidence rates after each injection. All local AEs were considered
vaccination-relatedbydeﬁnition. Irritabilitywas themost frequent-
ly reported systemic AE, but the occurrence decreased from86.5% to
62.3% from the ﬁrst to the third injection. No incidents of persistent
crying were reported, and unusual crying was reported only for one
subject after the ﬁrst vaccination.
There were no solicited vaccine-related SAEs reported during
the study period. One incident of sudden infant death syndrome
was reported, which the investigator assessed as being unrelated
to vaccination. Another 24 SAEs judged as unrelated to the study
vaccine were reported for 17 subjects; all recovered without
sequelae. There was one incidence of bronchiolitis that was
classiﬁed as vaccine-related by the investigator.
4. Discussion
The availability ofmultivalent vaccines plays an important role
in ensuring an increased compliance in the infant vaccination
programs recommended by the WHO. The acceptance of
multivalent vaccines largely depends on (1) their adaptability
to various vaccination schedules used in various countries; (2) the
demonstration that the included antigens do not negatively
inﬂuence each other’s immunogenicity; (3) the inclusion of
antigens that do not interfere with concomitant or preceding
vaccinations; and (4) the demonstration that the vaccine is safe
and well tolerated.
The present study showed that regardless of whether a birth
dose of HepB vaccine was administered or not, the fully liquid
pentavalent combination vaccine DTPw–HepB–Hib was immuno-
genic andwell toleratedwhen administered using a 2–4–6months
immunization schedule. Similar results have been achieved with
other multivalent vaccines in infants who had, or had not, received
HepB at birth.22,23 There was no inﬂuence of the birth dose of HepB
vaccine on the seroprotection or seroconversion rates against HBV,
Hib, diphtheria, tetanus, and B. pertussis after the primary
immunization course. Seroprotection and seroconversion rates
against HBV, Hib (0.15 mg/ml), diphtheria, tetanus, and B.
pertussis were also comparable to rates achieved with the same
vaccine after shorter intervals between doses,16 as well as to the
immunogenicity reported for an alternative pentavalent vac-
cine.12,13 Only in the evaluation where the anti-PRP 1.0 mg/ml
cut-off level was applied, was a slightly lower seroprotection rate
seen in both groups, as reported in a previous study.16 However,
the rate is comparablewith results achieved in a similar studywith
an alternative multivalent vaccine,23 as well as with the anti-PRP
1.0 mg/ml seroprotection rates achieved with a commercially
available monovalent Hib vaccine, which can be used in
combination with another multivalent vaccine for primary
immunization during the ﬁrst year of life.33
As expected, infantswho had receivedHepB vaccination at birth
achieved higher anti-HBs antibody GMTs after the primary
vaccination course. The difference in anti-HBs antibody titers
was, however, not likely to be clinically signiﬁcant, since long-term
epidemiologic studies have shown that infants who achieve anti-
HBs antibody titers >10 IU/l are protected for at least 10 to 20
years.34 Similarly, the difference in anti-tetanus titers between the
two study groups in the present studywas concluded to bewithoutclinical signiﬁcance because titers in both groups were well above
the seroprotective level.
Theadditionaldoseof amonovalentHepBvaccineatbirthdidnot
result in a clinically signiﬁcant increase in AEs, which was in
agreement with other studies.18–22 There was no marked impact of
the HepB vaccine birth dose on incidence rates, severity, or duration
of solicited local and systemic AEs, indicating that DTPw–HepB–Hib
was safe when administered to infants, whether or not they had
received a birth dose of HepB vaccine. The slightly increased
incidenceof fever in the ‘noHepBatbirth’ groupwasalsoobserved in
a similar study using another pentavalent vaccine.12 Although the
overall incidenceof local andsystemicAEswashigh in this study, the
clinical signiﬁcance of these eventswasmost likely low, because the
severity of the majority of local and unsolicited AEs was considered
mild. This was supported by the fact that the incidence rate of AEs
decreased during the vaccination course.
In conclusion, the current study demonstrated that the fully
liquid pentavalent combination vaccine DTPw–HepB–Hib was
immunogenic and well tolerated when administered in a 2–4–6
months immunization schedule, regardless of whether infants had
or had not received a birth dose of HepB vaccine.
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